Welcome to our dedicated page for Novo-Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo-Nordisk A/S stock.
Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk has launched a national campaign called The Power of Wegovy® to highlight the effectiveness of Wegovy® (semaglutide) 2.4 mg injection for weight management and cardiovascular risk reduction. The campaign aims to educate the public on the clinical benefits and safety of Wegovy® while addressing the stigma associated with obesity. The FDA-approved drug is used alongside a reduced-calorie diet and increased physical activity to aid weight loss and reduce major cardiovascular events in adults with heart disease. A recent FDA update has expanded its indications, and Novo Nordisk is working to improve drug access and insurance coverage.
Summary not available.
Novo Nordisk announced a significant reduction in the U.S. list prices for several insulin products by up to 75%, effective January 1, 2024. The price cuts apply to pre-filled pens and vials of both basal and bolus insulins, including NovoLog, Levemir, and Novolin. This initiative aims to enhance affordability for diabetes patients amidst ongoing healthcare price challenges. Novo Nordisk also offers co-pay support, allowing eligible patients to pay between $25 and $35 for their insulin. The company emphasizes its commitment to making insulin accessible and reducing out-of-pocket costs for patients.
Bigfoot Biomedical has announced the compatibility of its Bigfoot Unity Diabetes Management System with four additional rapid-acting insulin products, including Eli Lilly’s Insulin Lispro and Novo Nordisk’s Insulin Aspart. These insulins are offered at prices at least 50% lower than their branded counterparts, addressing the urgent need for affordable diabetes care. The system, which features smart pen caps compatible with various insulin pens, also includes Lilly’s Lyumjev, available for $35 under the Lilly Insulin Value Program, enhancing access for diabetes patients.
The STEP 5 phase 3b trial results for Wegovy™ (semaglutide) were presented at ObesityWeek 2021. Over two years, 304 adults using Wegovy™ achieved a 15.2% weight loss compared to 2.6% for placebo, with 77.1% of participants losing at least 5% of their body weight. Adverse events included nausea and diarrhea, with 5.9% of Wegovy™ patients discontinuing due to side effects. Approved by the FDA in June 2021, Wegovy™ aims to address the obesity epidemic, which affects more than 42% of adults in the U.S.
Novo Nordisk has announced pivotal results from the STEP clinical development program for semaglutide 2.4 mg, set to be presented at the ENDO Annual Meeting from March 20-23, 2021. The STEP program, involving approximately 4,500 adults, investigates obesity management's efficacy and safety. With findings that could aid in FDA approval, the trials include STEP 1 and STEP 2, focusing on weight loss and cardiometabolic health. The anticipated FDA decision follows a filing in December 2020, highlighting the drug's potential impact on obesity-related health issues.
Novo Nordisk has extended its COVID-19 Patient Assistance Program until June 30, 2021 to help individuals losing health insurance due to job changes from the pandemic. The program offers free insulin for 90 days to eligible patients. Additionally, those enrolled in the My$99Insulin program need to re-register for 2021 eligibility. Novo Nordisk also promotes various affordability initiatives, including the long-standing Patient Assistance Program and Copay Savings Cards. For details on eligibility and options, visit NovoCare.com.
Novo Nordisk has received FDA approval for an updated label for Saxenda® (liraglutide) 3 mg, allowing its use in adolescents (ages 12-17) with obesity. Saxenda, initially approved in 2014 for adults, now addresses a significant and growing need for effective treatments in youth, where obesity rates have doubled. The approval is supported by a phase 3a clinical trial showing significant reductions in BMI and weight compared to placebo. Common side effects include gastrointestinal issues. This move highlights the company's commitment to addressing adolescent obesity.